The DEA will have a hearing in December 2024 regarding the potential reclassification of cannabis to Schedule III, which could significantly impact the regulatory environment for pharmacies and their involvement in the cannabis market.
Frank Labrozzi
Advertisement
Articles by Frank Labrozzi
The opioid settlement framework could have a significant impact on the future of cannabis distribution and its role in health care.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments
2
FDA Expands Approval of Sotatercept-Csrk for Pulmonary Arterial Hypertension
3
First FDA-Approved Oral Liquid Sitagliptin for Adults with Type 2 Diabetes
4
Oxaliplatin as Part of Sequential Chemotherapy Shows Promise in Metastatic Pancreatic Cancer
5
